Navigation Links
Edwards Lifesciences Announces Schedule of Activities at TCT 2007
Date:10/16/2007

Program Includes Clinical Presentations Featuring Edwards' Interventional

Cardiovascular Technologies, Analyst Luncheon

IRVINE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced its schedule of activities for the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, from Oct. 20 through 25 in Washington, D.C.

Edwards will also host an analyst luncheon on Wednesday, Oct. 24, at 12:00 p.m. EDT. The featured speakers at the luncheon will be Augusto Pichard, M.D., Professor of Medicine and Director of the Cardiac Catheterization Laboratories, Washington Center Hospital, Washington, D.C., and Alex Powell, M.D., Interventional Radiologist, Baptist Cardiac and Vascular Institute, Miami, Fla.

Dr. Pichard will discuss his experiences with the Edwards SAPIEN transcatheter aortic heart valve and the RetroFlex transfemoral delivery system. He will also provide his perspective on the potential this valve replacement technology has in treating high-risk patients suffering from severe aortic stenosis.

Dr. Powell will discuss the one-year results from the RESILIENT trial, the landmark randomized study of the Edwards LifeStent Self-Expanding Stent for the treatment of peripheral vascular disease in the superficial femoral artery (SFA).

A live webcast of the presentation will be available on the Edwards investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm from 12:30 to 1:30 p.m. EDT. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.

In addition to the analyst luncheon, the TCT program will include a number of clinical presentations featuring several of Edwards' interventional cardiovascular technologies. Among the presentations are (all times EDT):

Sunday, Oct. 21

-- The Valvular Heart Disease Summit -- 8:00 a.m. to 7:00 p.m., Room

202B, co-sponsored by Edwards. The summit will cover topics including

mitral regurgitation therapies, transcatheter mitral valve repair and

replacement, transcatheter pulmonic valve replacement, aortic stenosis

and new devices. Presentations during the summit include: an overview

of Edwards' transcatheter heart valve replacement program, an update

on the status of the PARTNER pivotal trial for this device and interim

results from the EVOLUTION feasibility study, which utilizes Edwards'

MONARC system, a device intended to treat functional mitral

regurgitation in heart failure patients.

Monday, Oct. 22

-- Advanced Endovascular Techniques for the Treatment of Infrainguinal

Disease -- 7:00 a.m. to 8:00 a.m., Room 149AB, supported through an

educational grant by Edwards. The breakfast meeting will address

techniques and technologies for the treatment of infrainguinal

disease, as well as adjunct therapies.

Tuesday, Oct. 23

-- "Blockbuster" Trial of the Day: RESILIENT -- 11:00 a.m. to 12:00 p.m.,

Main Arena, Ballrooms ABC, Level 3. Presentations will address the

one-year results from the RESILIENT trial, the landmark randomized

study of the Edwards LifeStent Self-Expanding Stent in the SFA.

-- Hot Topics 2007/2008: Regulatory Pathways for Percutaneous Aortic

Valves -- 2:15 p.m. to 2:45 p.m., Room 207AB. Jodi J. Akin, Edwards

Lifesciences' vice president of clinical affairs, Heart Valve Therapy,

presents the industry perspective in a discussion with representatives

from the U.S. Food and Drug Administration, academia and industry

about clinical studies and regulatory approval for percutaneous

technology. Stanton Rowe, Edwards' corporate vice president, Advanced

Technology, will also serve as one of the discussants.

Wednesday, Oct. 24

-- Transcatheter Heart Valve Fundamentals from Science to Patient:

Edwards SAPIEN Transcatheter Heart Valve -- 7:00 a.m. to 8:00 a.m.,

Room 152A. The breakfast meeting will provide an overview of the

Edwards SAPIEN transcatheter valve's design, development and

performance in patients.

Representatives from Edwards will also be in the exhibition area at booth 5041 on level two.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards, Edwards SAPIEN, MONARC and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Doctors Hopeful for Elizabeth Edwards
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to improving ... health departments have been awarded national accreditation through the Public Health Accreditation ... expanding network of communities across the nation whose health departments meet rigorous national ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, ... Broadway Avenue, will be an educational and exciting program providing busy clinicians and ... of chronic pain. , Oklahoma is in a healthcare crisis. The state ranks ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... services firm serving the families and businesses of the Norwalk and Vermillion ... Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... to 2022" report to their offering. ... The global wound care market was worth $24,482.9 million ... 6.7% during 2016-2022 Among the various wound care products type, ... global market in 2015. Among the various applications, surgical wound segment held ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology: